S&P ASX All Technology

US Dollar vs AUD

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

DARE Dare Bioscience Inc

3.27

-0.03 (-0.91%)

28 Dec 2024 - Closed

Delayed by 15 minutes

Form D - Notice of Exempt Offering of Securities

Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From Nov 2024 to Dec 2024

Click Here for more Dare Bioscience Charts.

Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From Dec 2023 to Dec 2024

Click Here for more Dare Bioscience Charts.

Dare Bioscience Inc News

Form 8-K - Current report
Tuesday 17 December 2024 (2 weeks ago) • Edgar (US Regulatory)

Daré Bioscience Announces Phase 3 Plans for Sildenafil Cream, 3.6%, in the Treatment of Female Sexual Arousal Disorder (FSAD)
Tuesday 17 December 2024 (2 weeks ago) • GlobeNewswire Inc.

Daré Bioscience Announces Publication in Sexual Medicine of Positive Findings from Demographic, Behavioral and Medication Use Subgroup Analyses in the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6%
Wednesday 11 December 2024 (3 weeks ago) • GlobeNewswire Inc.

Daré Bioscience Announces $2.5 Million Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1
Thursday 5 December 2024 (3 weeks ago) • GlobeNewswire Inc.

Form EFFECT - Notice of Effectiveness
Wednesday 27 November 2024 (1 month ago) • Edgar (US Regulatory)

Form 424B3 - Prospectus [Rule 424(b)(3)]
Wednesday 27 November 2024 (1 month ago) • Edgar (US Regulatory)

Form S-1 - General form for registration of securities under the Securities Act of 1933
Saturday 16 November 2024 (1 month ago) • Edgar (US Regulatory)

Form 8-K - Current report
Friday 15 November 2024 (1 month ago) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Friday 15 November 2024 (1 month ago) • Edgar (US Regulatory)

Daré Bioscience Reports Third Quarter 2024 Financial Results and Provides Company Update
Friday 15 November 2024 (1 month ago) • GlobeNewswire Inc.

Daré Bioscience Announces Grant to Support Development of a Novel Non-Hormonal Contraceptive Candidate and Expansion of Ovaprene® Pivotal Study Clinical Trial Sites
Thursday 14 November 2024 (1 month ago) • GlobeNewswire Inc.

Daré Bioscience to Host Third Quarter 2024 Financial Results and Company Update Conference Call and Webcast on November 14, 2024
Friday 8 November 2024 (2 months ago) • GlobeNewswire Inc.

More Dare Bioscience Inc News Articles

Sterling vs AUD

Newcrest Mining

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions